Three Different Clocks Are Running Out on Mail-Order Ketamine, and Only One of Them Is About Safety

Three clocks are ticking on mail-order ketamine right now, and treating them as one story is how patients get blindsided.

Federal telehealth access is fine through December 31, 2026 — and nowhere near settled after that. DEA and HHS just issued their fourth straight extension of the pandemic-era rule letting prescribers put patients on Schedule II-V controlled substances — ketamine is Schedule III, the federal tier for drugs with real abuse potential that still have accepted medical uses — over video with no in-person exam first, per the Federal Register notice published December 31, 2025. DEA has floated a permanent “Special Registration for Telemedicine” system to replace these stopgaps since 2023 and is still sitting on more than 6,000 public comments. Nobody at DEA has committed to finalizing it before this extension also expires — the same regulatory limbo playing out across the telehealth industry for every controlled substance, not just this one.

Every mail-order ketamine prescription you can get today exists because that federal clock hasn’t run out yet — not because anyone decided at-home ketamine is safe.

Those are different questions, and Texas just supplied the sharpest illustration of why. The Texas Medical Board isn’t touching telehealth law — it can’t, that’s a DEA lane — but it is moving to ban at-home ketamine use outright under its own licensing authority — the state’s separate power over who can practice medicine and how — requiring a physician on-site for every dose and mandatory clinic registration, with a board vote teed up for June, per Texas Tribune reporting. State Rep. Tom Oliverson, an anesthesiologist who sat on the board, put the split plainly: “People think ketamine is a wellness treatment when it’s not.” A federal carve-out means nothing in a state that has separately banned unsupervised use: DEA can keep the prescribing pathway open while Texas closes the delivery pathway on the ground.

The clinical case for tightening is not theoretical. STAT News combed patient reports and found dosing running 50mg to 800mg against the FDA-approved nasal spray Spravato’s hard 84mg ceiling — a sixteen-fold spread with no clinician in the room to catch it. The same reporting cites companies including Mindbloom, which has logged hundreds of thousands of at-home sessions and now faces a wrongful-death lawsuit alleging inadequate oversight during an overdose. If you’re one of the patients getting ketamine mailed to your door right now: ask your prescriber, in writing, what happens if you become unresponsive alone in your apartment. If they can’t answer that, that’s your answer.

A third, unrelated clock belongs to the FDA, not DEA or any state board: a generic-drug approval decision, due by its July 29, 2026 goal date, on NRx Pharmaceuticals’ KETAFREE, a preservative-free IV formulation meant to replace Benzethonium Chloride, the preservative in today’s multi-dose vials that the FDA does not recognize as safe, per the company’s FDA filing announcement. That decision changes what’s in the vial. It says nothing about who’s allowed to prescribe it to your bedroom, and it will land squarely between the Texas vote and the DEA’s year-end deadline without resolving either.

None of these three bodies is waiting on the other two, and the industry built on the assumption they’d stay frozen together is the one about to find out they won’t.